Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Captopril
Drug ID BADD_D00354
Description Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment of hypertension.
Indications and Usage For the treatment of essential or renovascular hypertension (usually administered with other drugs, particularly thiazide diuretics). May be used to treat congestive heart failure in combination with other drugs (e.g. cardiac glycosides, diuretics, β-adrenergic blockers). May improve survival in patients with left ventricular dysfunction following myocardial infarction. May be used to treat nephropathy, including diabetic nephropathy.
Marketing Status approved
ATC Code C09AA01
DrugBank ID DB01197
KEGG ID D00251
MeSH ID D002216
PubChem ID 44093
TTD Drug ID D0I0EG
NDC Product Code 27241-162; 31722-141; 31722-142; 0143-1171; 63629-8728; 69292-526; 53296-0031; 31722-144; 0143-1174; 60687-304; 63629-1338; 63629-8730; 0781-8061; 0904-7105; 63629-8729; 70518-3307; 71335-1918; 51552-1072; 51927-0137; 27241-160; 27241-161; 43547-363; 63629-8727; 69292-522; 71335-0826; 0781-8052; 53069-0150; 31722-143; 27241-163; 51407-601; 51407-602; 51407-603; 43547-366; 55289-344; 0781-8080; 55488-0600; 43547-364; 0781-8075; 0143-1172; 0143-1173; 43547-365; 50090-5964; 51407-600; 60687-315; 69292-524; 69292-528; 0904-7106
UNII 9G64RSX1XD
Synonyms Captopril | (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline | Lopirin | SQ-14,534 | SQ 14,534 | SQ14,534 | SQ-14534 | SQ 14534 | SQ14534 | Capoten | SQ-14,225 | SQ 14,225 | SQ14,225 | SQ-14225 | SQ 14225 | SQ14225
Chemical Information
Molecular Formula C9H15NO3S
CAS Registry Number 62571-86-2
SMILES CC(CS)C(=O)N1CCCC1C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Protein urine present13.13.02.006--Not Available
Epigastric discomfort07.01.02.004--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Thermal burn23.03.11.042; 12.05.04.001--
Hypoaesthesia oral17.02.06.021; 07.05.05.0030.000488%Not Available
Cerebrovascular insufficiency24.04.06.004; 17.08.02.003--Not Available
Urine output increased13.13.03.002--Not Available
Antinuclear antibody positive13.06.01.003--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction21.03.01.007; 19.08.04.001--
Ill-defined disorder08.01.03.049--Not Available
Obstructive airways disorder22.03.01.011--Not Available
Renal impairment20.01.03.0100.000732%Not Available
Muscle contracture15.03.05.024--Not Available
Lichenoid keratosis23.01.01.0040.000732%Not Available
Chronic kidney disease20.01.03.017--
Liver injury12.01.17.012; 09.01.07.022--Not Available
Cholestatic liver injury09.01.07.0160.000732%Not Available
Traumatic liver injury12.01.17.027; 09.01.08.010--Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.0040.000488%
Acute kidney injury20.01.03.0160.000732%
Microsomia08.01.03.056--Not Available
Drug-induced liver injury12.03.01.044; 09.01.07.0230.000732%Not Available
Drug reaction with eosinophilia and systemic symptoms12.03.01.064; 23.03.05.005; 10.01.01.0210.000975%Not Available
Irregular sleep wake rhythm disorder19.02.06.005; 17.15.06.005--Not Available
Polyglandular autoimmune syndrome type III10.04.08.003; 05.09.02.0030.000732%Not Available
The 7th Page    First    Pre   7    Total 7 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene